|
|||||
|
|
Standard PAH therapy improves long term survival in CTEPH patients |
|
| Authors: | Hans-Juergen Seyfarth Michael Halank Heinrike Wilkens Hans-Joachim Schäfers Ralf Ewert Martin Riedel Ernst Schuster Hans Pankau Stefan Hammerschmidt Hubert Wirtz |
| Affiliation: | 1. Department of Respiratory Medicine, University of Leipzig, Liebigstrasse 20, 04103, Leipzig, Germany 2. Internal Medicine I, University of Dresden, Dresden, Germany 3. Universit?tsklinikum Homburg/Saar, Homburg, Germany 4. University of Greifswald, Greifswald, Germany 5. Deutsches Herzzentrum, Klinikum Der TU München, Munich, Germany 6. Institut for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany |
| Abstract: | BackgroundChronic thromboembolic pulmonary hypertension (CTEPH), subsequent to pulmonary embolism is a relatively frequent cause of pulmonary hypertension. Similar to patients with pulmonary arterial hypertension (PAH), CTEPH carries a poor prognosis. There is no hard evidence for any other therapy except pulmonary endarterectomy and none for those patients that are not eligible for this procedure.Patients and methodsFifty patients with confirmed, inoperable CTEPH receiving specific vasodilative therapy (prostanoids, endothelin receptor antagonists, PDE 5-inhibitors or combination) were included in this retrospective study (mean age 55 years, range 16–76 years; 36 female, 14 male). Kaplan–Meier plots of these patients were compared with Kaplan–Meier plots of two historical CTEPH patient groups without any specific vasodilative treatment by log rank tests.ResultsCTEPH patients treated with specific vasodilative compounds as used for therapy of PAH were followed up for 52 ± 30 months and had a significantly improved survival compared with patients treated without PAH type vasodilators (p ≤ 0.0002).ConclusionOur data may generate the hypothesis that specific vasodilative treatment improves outcome in patients with inoperable CTEPH. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |